Several parties interested in Northwest Biotherapeutics' immunotherapy cancer vaccines

Last week, a detailed report authored by research pharmaceutical analyst Navid Malik caused some excitement in the pharmaceutical industry about Northwest Biotherapeutics' DCVax immunotherapy vaccines to treat cancer.

In an interview with BioMedReports, Northwest's chairperson Linda Powers says: "I can tell you that the company has received multiple inquiries about DCVax prostate, not surprisingly in the post-Dendreon period, from big pharma as well as financial parties, and we think it will be a huge newsworthy event when we do that transaction.'

She went onto say: 'We've begun focusing on that and we're allowing ourselves some time to get the right transaction done. That, I think, will be a major milestone kicking off, especially if we go the route of a partnering deal. Obviously, that would be a major announcement and event.'